Skip to content

19-362 - Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Status: open

A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Treatment for Advanced Solid Tumors

Contact Us

Description


The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of  MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy  will be for up to 35 administrations (approximately 2 years). The safety and pharmacokinetics of MK-5890 when administered with pembrolizumab, pemetrexed and carboplatin will also be assessed in adults with non-squamous non-small cell lung cancer (NSCLC).

Sponsors

This trial is sponsored by University of Chicago.

Providers Associated With This Trial

Principle Investigator

    Sub Investigators

    This link will open in a new tab or window.